ライフサイエンスコーパス: we enrolled patients

1 We enrolled patients 6 months of age or older who presented w

2 In a prospective, controlled observational cohort study, we enrolled patients admitted due to acute respiratory illnes

3 We enrolled patients admitted to hospital with suspected or c

4 We enrolled patients aged 13 years or older with functional C

5 In this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloi

6 We enrolled patients aged 18 years or older with HCV genotype

7 In this phase 1 study, we enrolled patients aged 18 years or older with myelodysplas

8 We enrolled patients aged 18 years or older with spontaneous,

9 e, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabe

10 We enrolled patients aged 20 years and older with unresectabl

11 this multicenter, prospective, observational cohort study, we enrolled patients aged 6 months to 18 years with newly pla

12 We enrolled patients aged 65 years or younger with previously

13 We enrolled patients (aged >=18 years) with a diagnosis of mu

14 In this open-label, single-arm, phase 1-2 trial, we enrolled patients (aged >=18 years) with histologically or

15 We enrolled patients (aged 3-64 years) presenting to two Kath

16 In this double-blind, placebo-controlled trial (DELIGHT), we enrolled patients at 116 research centres in Australia, Ca

17 randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral sites in North America, E

18 We enrolled patients between Oct 27, 2010, and Feb 13, 2013,

19 We enrolled patients from across the US National Clinical Tri

20 We enrolled patients from five academic PICUs between 2008 an

21 randomised, double-blind, comparative effectiveness trial, we enrolled patients from six tertiary medical centres in the

22 We enrolled patients who had at least one attack every other

23 We enrolled patients who had squamous or non-squamous non-sma

24 We enrolled patients who progressed after one to two lines of

25 We enrolled patients who underwent kidney transplantation and

26 nter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart fa

27 We enrolled patients with a controlled primary malignancy and

28 , multicentre, double-blind, phase 3 non-inferiority study, we enrolled patients with active Crohn's disease who had not

29 d study done in 48 acute care hospitals in eight countries, we enrolled patients with acute ischaemic stroke due to large

30 In this noninterventional, retrospective study, we enrolled patients with allergic rhinitis and sensitization

31 We enrolled patients with atherosclerotic cardiovascular dise

32 multicenter, non-inferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who h

33 ter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocard

34 We enrolled patients with heart failure with reduced ejection

35 In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary a

36 We enrolled patients with locally advanced and/or metastatic

37 In this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assig

38 We enrolled patients with metastatic RCC with no prior checkp

39 In this ongoing phase 3 trial in 23 countries, we enrolled patients with multidrug-resistant HIV-1 infection

40 We enrolled patients with occlusion of the intracranial inter

41 In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hy

42 In phase 1b, we enrolled patients with PD-L1-positive tumours in a 3 + 3 d

43 We enrolled patients with primary refractory or relapsed myel

44 s global, open-label, randomised, controlled phase 3 trial, we enrolled patients with relapsed CLL progressing less than

45 We enrolled patients with RET-mutant medullary thyroid cancer

46 We enrolled patients with sickle cell disease in a single-cen

47 In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma

48 Last, we enrolled patients with stage D HF and sampled their blood

49 We enrolled patients with treatment-refractory metastatic SCC

50 From 2000 to 2015, we enrolled patients younger than 50 years of age with newly